OBP-301

Phase 2Biologic

OOncolys BioPharma Inc

OBP-301 is one of 38 biologic programs targeting Gastric Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaRecruiting

Gastric AdenocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

38 competitors in Gastric Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

16 2

Tukysa

Gleevec

Tegretol

Koselugo

Taxol

14 7

Keytruda

Merck & Co.

Phase 3

4 8

Opdivo

Bristol-Myers Squibb

Phase 3

3 9

Elunate

Takeda

Phase 3

1 10

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Gastric Adenocarcinoma

NCT06340711

Clinical

Trials by Indication[1]

Esophageal Cancer1 trial

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Unknown status·OOncolys BioPharma Inc·Phase 1·NCT03213054·12 enrolled

Progressive Disease1 trial

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04685499·1 enrolled

Metastatic Melanoma1 trial

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Unknown status·SSyneos Health·Phase 2·NCT03190824·4 enrolled

Hepatocellular Carcinoma1 trial

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Unknown status·OOncolys BioPharma Inc·Phase 1·NCT02293850·18 enrolled

Pembrolizumab1 trial

Special Combination of OBP-301 and Pembrolizumab

Completed·TToshihiko Doi·Phase 1·NCT03172819·22 enrolled

1 more indication

Gastric Adenocarcinoma1 trial

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06340711·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for OBP-301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OBP-301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OBP-301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncolys BioPharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOncolys BioPharma Inc

OBP-301

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Esophageal Cancer1 trial

Progressive Disease1 trial

Metastatic Melanoma1 trial

Hepatocellular Carcinoma1 trial

Pembrolizumab1 trial

Gastric Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News